FR2844520B1 - Utilisation d'un anticorps induisant la secretion de cytokines en therapie - Google Patents
Utilisation d'un anticorps induisant la secretion de cytokines en therapieInfo
- Publication number
- FR2844520B1 FR2844520B1 FR0211415A FR0211415A FR2844520B1 FR 2844520 B1 FR2844520 B1 FR 2844520B1 FR 0211415 A FR0211415 A FR 0211415A FR 0211415 A FR0211415 A FR 0211415A FR 2844520 B1 FR2844520 B1 FR 2844520B1
- Authority
- FR
- France
- Prior art keywords
- cytokines
- secretion
- therapy
- antibody inducing
- inducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (36)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0211415A FR2844520B1 (fr) | 2002-09-13 | 2002-09-13 | Utilisation d'un anticorps induisant la secretion de cytokines en therapie |
FR0307066A FR2844455B1 (fr) | 2002-09-13 | 2003-06-12 | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
FR0307067A FR2844513B1 (fr) | 2002-09-13 | 2003-06-12 | Anticorps pour adcc et induisant la production de cytokines. |
CA2498383A CA2498383C (fr) | 2002-09-13 | 2003-09-15 | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
EP15182965.2A EP3001198A1 (fr) | 2002-09-13 | 2003-09-15 | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
PCT/FR2003/002714 WO2004028564A2 (fr) | 2002-09-13 | 2003-09-15 | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
AU2003282160A AU2003282160A1 (en) | 2002-09-13 | 2003-09-15 | Antibody for adcc and inducing cytokine production |
ES03773780T ES2362652T3 (es) | 2002-09-13 | 2003-09-15 | Procedimiento de evaluación de la eficacia adcc mediada por el cd16 de anticuerpos monoclonales o policlonales. |
EP03775438A EP1545614A2 (fr) | 2002-09-13 | 2003-09-15 | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
AU2003282161A AU2003282161B2 (en) | 2002-09-13 | 2003-09-15 | Cytokine production-inducing antibody |
EP03773779A EP1537147B9 (fr) | 2002-09-13 | 2003-09-15 | Anticorps anti hla-dr ayant une adcc augmentée et induisant la production de cytokines. |
JP2004539109A JP2006516951A (ja) | 2002-09-13 | 2003-09-15 | Adccおよびサイトカイン産生の誘導のための抗体 |
EP03773780A EP1537419B1 (fr) | 2002-09-13 | 2003-09-15 | Procédé d'évaluation de l'efficacité ADCC médiée par le CD16 d'anticorps monoclonaux ou polyclonaux |
AT03773779T ATE486094T1 (de) | 2002-09-13 | 2003-09-15 | Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren |
US10/527,666 US20050271652A1 (en) | 2002-09-13 | 2003-09-15 | Treatment of pathologies which escape the immune response, using optimised antibodies |
PCT/FR2003/002715 WO2004024768A2 (fr) | 2002-09-13 | 2003-09-15 | Anticorps induisant la production de cytokines |
US10/527,665 US7595165B2 (en) | 2002-09-13 | 2003-09-15 | Method of measuring activation of effector cells |
PCT/FR2003/002713 WO2004029092A2 (fr) | 2002-09-13 | 2003-09-15 | Anticorps pour adcc et induisant la production de cytokines. |
AT03773780T ATE511654T1 (de) | 2002-09-13 | 2003-09-15 | Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern |
EP09152731A EP2092939A3 (fr) | 2002-09-13 | 2003-09-15 | Utilisation thérapeutique d'anticorps induisant la production de cytokines |
JP2004539110A JP2006504700A (ja) | 2002-09-13 | 2003-09-15 | 最適化抗体を用いた、免疫応答を逃れる病態の治療法 |
JP2004535611A JP4368800B2 (ja) | 2002-09-13 | 2003-09-15 | サイトカイン産生誘導抗体 |
AU2003283469A AU2003283469C1 (en) | 2002-09-13 | 2003-09-15 | Treatment of pathologies which escape the immune response, using optimised antibodies |
CA002498787A CA2498787A1 (fr) | 2002-09-13 | 2003-09-15 | Anticorps pour adcc et induisant la production de cytokines |
DK03773780.6T DK1537419T3 (da) | 2002-09-13 | 2003-09-15 | Test for CD16-medieret ADCC effektivitet af monoklonale og polyklonale antistoffer |
DE60334700T DE60334700D1 (de) | 2002-09-13 | 2003-09-15 | Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren |
CA2498315A CA2498315C (fr) | 2002-09-13 | 2003-09-15 | Anticorps induisant la production de cytokines |
US10/527,664 US20060127392A1 (en) | 2002-09-13 | 2003-09-15 | Antibody for adcc and inducing cytokine production |
IL167385A IL167385A (en) | 2002-09-13 | 2005-03-10 | Method for selecting a monoclonal antibody for increased antibody-dependent cellular cytotoxicity activity |
IL167381A IL167381A (en) | 2002-09-13 | 2005-03-10 | Use of an Enhanced Monoclonal Antibody to Prepare a Pharmaceutical Compound for the Treatment of Immune Response Diseases |
US12/234,609 US20090081216A1 (en) | 2002-09-13 | 2008-09-19 | Treatment of pathologies which escape the immune response, using optimized antibodies |
JP2009190989A JP5951923B2 (ja) | 2002-09-13 | 2009-08-20 | 最適化抗体を用いた、免疫応答を逃れる病態の治療法 |
US12/585,900 US20100323368A1 (en) | 2002-09-13 | 2009-09-28 | Cytokine production-inducing antibody |
US12/576,202 US20100145026A1 (en) | 2002-09-13 | 2009-10-08 | Antibody for ADCC And Inducing Cytokine Production |
IL230101A IL230101A (en) | 2002-09-13 | 2013-12-23 | Use of fine antibodies to make drugs to treat pathological evasion of immune response |
JP2013272030A JP6238743B2 (ja) | 2002-09-13 | 2013-12-27 | 最適化抗体を用いた、免疫応答を逃れる病態の治療法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0211415A FR2844520B1 (fr) | 2002-09-13 | 2002-09-13 | Utilisation d'un anticorps induisant la secretion de cytokines en therapie |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2844520A1 FR2844520A1 (fr) | 2004-03-19 |
FR2844520B1 true FR2844520B1 (fr) | 2006-06-09 |
Family
ID=31897390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0211415A Expired - Lifetime FR2844520B1 (fr) | 2002-09-13 | 2002-09-13 | Utilisation d'un anticorps induisant la secretion de cytokines en therapie |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2362652T3 (fr) |
FR (1) | FR2844520B1 (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4070500A (en) * | 1999-04-05 | 2000-10-23 | Biocrystal Limited | Assay kits and methods for immune complex-mediated activation involving shed antigens |
FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
-
2002
- 2002-09-13 FR FR0211415A patent/FR2844520B1/fr not_active Expired - Lifetime
-
2003
- 2003-09-15 ES ES03773780T patent/ES2362652T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
FR2844520A1 (fr) | 2004-03-19 |
ES2362652T3 (es) | 2011-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR16C1012I2 (fr) | Utilisation therapeutique d'anticorps anti-cs1 | |
ATE318590T1 (de) | Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen | |
ITMI20011083A0 (it) | Dispositivo per l'igiene dentale | |
EE200100370A (et) | Teraapias kasutatavad spirofuropüridiinide uued aralküülamiinid | |
EE200200286A (et) | Uued aminopropüülfosfiinhapped ning nende kasutamine | |
IS6966A (is) | Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
IS6967A (is) | Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
DK1114821T3 (da) | Benzopyraner og disses anvendelse som terapeutiske midler | |
FR2747230B1 (fr) | Bouton d'arret d'urgence cadenassable | |
AU2003301843A8 (en) | 157 human secreted proteins | |
FR2844520B1 (fr) | Utilisation d'un anticorps induisant la secretion de cytokines en therapie | |
MA27184A1 (fr) | Dosage d'anticorps anti-ingap | |
FR2804320B1 (fr) | Composition cosmetique favorisant la respiration cellulaire | |
ITMI20011404A0 (it) | Preparazione dietetica ed attivita' ipocolesterololemizzante | |
ITMI20032291A1 (it) | Procedimento e dispositivo per l'approntamento di un combustibile | |
IT1296032B1 (it) | Carrello semovente trasportabile con sedia amovibile standard per persone con problemi di deambulazione utilizzabile negli interni | |
NO20010630L (no) | Krummet trapp og trappetrinn for krummet trapp | |
FR2837707B1 (fr) | Utilisation de la 8'-hydroxydihydroergotamine pour un medicament anxiolytique | |
NO20023003L (no) | Benzofenon-glykopyranosider, samt fremstilling og terapeutisk anvendelse | |
ID27282A (id) | Protein c polipeptida pada manusia | |
ITPD20020240A1 (it) | Dispositivo per la separazione e l'immagazzinamento | |
NO20000275D0 (no) | Alfs slipsholder | |
ATE419001T1 (de) | Melanoma therapie | |
SE9702595D0 (sv) | new therapeutic use | |
IT1290455B1 (it) | Uso di antiossidanti per la preparazione di medicamenti utili per il trattamento di flebopatie e patologie vascolari ischemiche croniche |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TP | Transmission of property | ||
TP | Transmission of property |
Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR Effective date: 20130903 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |